Increasing Access To Biosimilars Act Of 2023

AI Summary

The "Increasing Access to Biosimilars Act of 2023" aims to enhance access to biosimilar medications in the United States. The bill includes provisions to expedite the approval process for biosimilars, promote competition in the biologics market, and increase patient access to more affordable treatment options. It seeks to streamline regulatory pathways, encourage innovation, and reduce healthcare costs by fostering a more competitive market for these complex biologic drugs. The bill's key focus is on expanding patient choice, improving affordability, and promoting a more efficient healthcare system through increased availability of biosimilars as alternatives to costly brand-name biologics.

• 2023-03-03: Introduced in House

• 2023-03-03: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

• 2023-03-10: Referred to the Subcommittee on Health.

• 2023-11-15: Subcommittee Consideration and Mark-up Session Held

• 2023-11-15: Forwarded by Subcommittee to Full Committee by Voice Vote.

• 2023-12-05: Committee Consideration and Mark-up Session Held

• 2023-12-06: Ordered to be Reported (Amended) by the Yeas and Nays: 44 - 0.